Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
PMV Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology therapies. The company operates within the biotechnology and oncology drug development industries, with a core scientific focus on restoring the tumor-suppressor function of mutated p53 proteins, one of the most commonly altered pathways in human cancer. PMV Pharmaceuticals’ strategy centers on small-molecule therapeutics designed to selectively target genetically defined cancer subtypes.
The company’s primary value driver is its proprietary p53 reactivation platform, with its lead product candidate rezatapopt (PC14586) targeting the TP53 Y220C mutation. PMV Pharmaceuticals serves oncology patients with specific genetic mutations, primarily through partnerships with clinical investigators and oncology centers. The company was founded in 2013 and became publicly traded in 2020, evolving from a research-focused startup into a clinical-stage company with ongoing late-stage clinical development programs.
Business Operations
PMV Pharmaceuticals operates as a single-segment company focused on oncology drug discovery and development, generating no commercial revenue as of the most recent public filings. Its operations are centered on internal research and development, clinical trials, regulatory activities, and intellectual property management related to p53-targeted therapeutics. The company’s pipeline is built on proprietary small-molecule design technology aimed at selectively stabilizing mutant p53 proteins.
Operations are primarily based in the United States, with international clinical trial activity conducted through third-party contract research organizations and academic collaborators. PMV Pharmaceuticals does not currently report material revenue-generating subsidiaries or joint ventures. Its assets consist mainly of drug candidates, clinical data, and intellectual property developed internally and supported by external research partnerships.
Strategic Position & Investments
PMV Pharmaceuticals’ strategic direction is focused on advancing rezatapopt (PC14586) through late-stage clinical development while expanding its pipeline of mutation-specific p53 reactivators. Growth initiatives are centered on clinical trial expansion, regulatory engagement, and potential future commercialization strategies for genetically defined cancer indications. The company positions itself as a leader in precision oncology targeting structurally defined oncogenic mutations.
The company has not announced major acquisitions or diversified portfolio investments, instead allocating capital toward internal R&D and clinical execution. PMV Pharmaceuticals continues to invest in next-generation p53 programs designed to address additional TP53 mutations, representing an emerging and highly specialized area of oncology drug development. Data on material equity investments or external portfolio companies is inconclusive based on available public sources.
Geographic Footprint
PMV Pharmaceuticals is headquartered in Princeton, New Jersey, which serves as its primary center for corporate management and research operations. The company’s activities are predominantly based in North America, with clinical trial sites distributed across the United States and selected international locations to support global patient enrollment.
While the company does not maintain significant physical operations outside the United States, its international footprint is reflected through global clinical trials and regulatory interactions in multiple regions. PMV Pharmaceuticals does not currently report significant commercial operations or manufacturing facilities in other geographic markets.
Leadership & Governance
PMV Pharmaceuticals was co-founded by David Mack, who has played a central role in shaping the company’s scientific and strategic vision around p53-targeted oncology therapies. The leadership team emphasizes a science-driven, precision medicine approach, prioritizing genetically defined patient populations and rigorous clinical validation.
Key members of the leadership team include:
- David Mack, PhD – President and Chief Executive Officer
- Adam Koppel – Chief Financial Officer
- Anil D’Cruz, PhD – Chief Operating Officer
The company is governed by a board of directors with experience in biotechnology, drug development, and capital markets. Leadership philosophy centers on disciplined capital allocation, deep scientific expertise, and long-term value creation through targeted oncology innovation.